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AbstrAct
In the last five years, everolimus has demonstrated efficacy in the treatment 
of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were 
explored in the RADIANT trials, the last of which (RADIANT-4) has been recently 
published (December 2015). Overall, evidence collected from the RADIANT studies 
holds promise to change clinical practice for the treatment of NETs.
In this paper, we comment on the role of everolimus within the therapeutic 
algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials 
and our experience.
IntroductIon
The incidence of neuroendocrine tumors (NETs) is 
increasing worldwide [1]. NETs represent a heterogeneous 
class of neoplasms, with tumor behavior - and therefore 
patient survival - depending upon several factors including 
primary site, tumor histology, proliferative index, and 
staging [2]. The management of NETs is challenging, 
and only few therapeutic options are currently available. 
In recent years, targeted therapies such as sunitinib and 
everolimus have been tested for the treatment of NETs, 
with overall satisfactorily results [3]. 
The phosphatidylinositol 3-kinase (PI3K)/AKT/
mammalian target of rapamycin (mTOR) pathway plays 
a central role in the regulation of cell proliferation, 
apoptosis, cell cycle, metabolism, and angiogenesis [4]. 
Of note, a number of studies have suggested that the PI3K/
AKT/mTOR signaling pathway is strongly implicated 
in the pathogenesis and progression of neuroendocrine 
tumors [4-9]. Therefore, a targeted therapy able to directly 
inhibit the mTOR pathway, e.g. everolimus, does represent 
a particularly suitable strategy for the treatment of NETs.
In the last five years, everolimus has demonstrated 
activity in the treatment of NETs of different origins; 
its efficacy and safety were explored in the RADIANT 
trials, the last of which (RADIANT-4) was published in 
December 2015 [10-13]. Overall, evidence collected from 
the RADIANT studies holds promise to change clinical 
practice in the treatment of NETs.
In this paper, we provide our personal view on how 
do the results of the RADIANT studies impact on the 
management of NET patients, and we comment on the role 
of everolimus within the therapeutic algorithm for NETs 
treatment on the basis of the systematic analysis of the 
RADIANT trials and our experience. 
EvIdEncE collEctIon
Papers for consideration in this manuscript were 
collected based on a PubMed search, using pertinent 
keywords (‘RADIANT’ AND ‘Neuroendocrine tumors’ 
AND everolimus). No limitations in terms of language 
or publication date were applied. The first search was 
last updated on December 10th 2015, and it was then 
supplemented by manually browsing the reference 
section of identified papers; studies included to authors’ 
personal collection of literature were considered as well. 
A supplementary research was conducted at the revision 
of the paper (March 2016).
Papers were then selected for inclusion on the basis 
of their relevance for the topic, as judged by the authors.
                                                         Review
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thE rAdIAnt studIEs
rAdIAnt 1
The rationale for the RADIANT 1 study was based 
upon the results of a preliminary Phase II study, in which 
patients with advanced low-intermediate carcinoid or islet 
cells NETs received everolimus 5 mg/day (n = 30) or 10 
mg/day (n = 30) and octreotide LAR 30 mg every 28 days 
[5]. Overall, the response rate (RR) was 20% at the intent-
to-treat analysis; at the per protocol analysis, there were 13 
partial responses (PRs) (22%) and 42 stable diseases (SDs; 
70%). Median progression-free survival (PFS) was 60 
weeks, and the 3-year survival rate was 78%. Main grade 
3/4 toxicities were hypophosphatemia (11%), fatigue 
(11%), and diarrhea (11%). 
The above-mentioned findings paved the way 
for the international RADIANT 1 study. This open-
label, Phase II trial evaluated the efficacy and safety of 
everolimus in patients with metastatic pancreatic NET 
(pNET) who progressed on chemotherapy [10]. Patients 
were stratified by prior octreotide therapy (stratum 1: 
everolimus 10 mg/day, n = 115; stratum 2: everolimus 
10 mg/day plus octreotide long-acting release [LAR], 
n = 45). At central analysis, 11 PRs (9.6%) and 78 SDs 
(67.8%) were reported in stratum 1; median PFS was 9.7 
months. In stratum 2, there were two PRs (4.4%), while 36 
patients (80%) achieved SD; progression of disease (PD) 
was never observed. In this group, median PFS was 16.7 
months. The authors of the RADIANT 1 trial concluded 
that daily everolimus, either with or without concomitant 
octreotide LAR, showed promising antitumor activity and 
was well tolerated in patients with advanced pNETs after 
failure of prior systemic chemotherapy. 
rAdIAnt 2
In the international randomized, double-blind, 
placebo controlled phase III RADIANT 2 trial, the 
combination of everolimus (10 mg/day) plus octreotide 
LAR was compared with octreotide LAR alone in 429 
patients with low-grade or intermediate-grade NET 
associated with carcinoid syndrome [11]. The primary 
endpoint was PFS; its median values were 16.4 months 
in the everolimus plus octreotide LAR group and 11.3 
months in octreotide LAR-only group, respectively 
(hazard ratio [HR] 0.77, 95% CI 0.59-1.00). In line with 
the results of the RADIANT 1 study, most drug-related 
adverse events were of grade 1 or 2; most frequent adverse 
events (all grades) included stomatitis (62% vs 14%), rash 
(37% vs 12%), fatigue (31% vs 23%), and diarrhea (27% 
vs 16%). 
Of note, three major imbalances should be taken 
into account when considering the findings of the 
RADIANT 2 trial. First, WHO performance status was 
less favorable in the everolimus arm compared with the 
placebo arm. Second, there was a higher incidence of 
pulmonary primary tumors in the everolimus arm (15% 
vs 5%). Third, patients assigned to the combination arm 
had a more frequent prior used of chemotherapy. Also due 
- at least in part - to those imbalances, this study did not 
reach statistical significance with respect to PFS; statistical 
significance was pre-specified to be set at 0.0246, and it 
was actually 0.026. 
On the other hand, the results of a number of 
subgroup analyses of the RADIANT 2 lend support to the 
efficacy of everolimus. In a sub-analysis including only 
patients with lung NET (everolimus plus octreotide LAR, 
n = 33; octreotide LAR only, n = 11), median PFS was 2.4-
fold longer in the combination arm (13.6 vs 5.6 months), 
with a 28% reduction in the risk of progression (HR, 0.72; 
95% CI 0.31-1.68) [14]. More patients on everolimus plus 
octreotide LAR (67%) experienced tumor shrinkage than 
those receiving octreotide LAR only (27%). The safety 
profile was consistent with the results of the core trial. The 
authors of this sub-analysis suggested that the advantage 
for everolimus+octreotide LAR over octreotide LAR 
alone was clinically-relevant, and therefore supported 
the continued evaluation of everolimus in patients with 
lung NETs. Overall, similar findings were reported in the 
subgroup analysis of patients with colorectal NETs [15]. 
In this analysis, patients assigned to the combination arm 
(n = 19) experienced a significantly longer median PFS 
(29.9 months) than those on octreotide LAR only (6.6 
months; n = 20). Everolimus plus octreotide LAR also 
determined a significant reduction in the risk of disease 
progression (HR: 0.34; 95% CI 0.13-0.89; p = 0.011). 
Although no objective responses were observed, tumor 
shrinkage was more frequently reported with combination 
treatment (67% vs 37%). Last, another recently published 
sub-analysis of the RADIANT 2 trial evaluated the impact 
of previous treatment with somatostatin analogue (SSA) 
on the safety and efficacy of everolimus [16]. In total, 339 
patients enrolled in the trial were previously exposed to 
SSAs. Overall, more patients on previous SSA therapy 
had a history of flushing symptoms (77%), diarrhea (86%), 
or both (63%) compared with SSA-naive subjects (62%, 
62%, and 24%, respectively). Of note, patients in the 
combination arm showed longer median PFS regardless 
of previous SSA exposure (with: PFS 14.3 months, 95% 
CI 12.0-20.1; without: 25.2 months, 95% CI, 12.0-NR) 
than those on octreotide LAR only (with: 11.1 months, 
95% CI 8.4-14.6; without: 13.6 months, 95% CI 8.2-22.7).
rAdIAnt 3
The international randomized, placebo-controlled, 
phase III RADIANT 3 trial was the largest study ever 
conducted in the setting of NETs [12]. In this trial, 410 
patients with advanced, low-grade or intermediate-grade 
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pNET who showed radiologic progression within the 
previous 12 months before enrolment were randomly 
assigned to receive everolimus (10 mg/day; n = 207) or 
placebo (n = 203), both associated with best supportive 
care. The primary endpoint was PFS. If radiologic 
progression occurred during the study, patients assigned 
to placebo were offered open-label everolimus. Median 
PFS was significantly longer in the everolimus group, 
compared with controls. In more details, it was 11.0 
months with everolimus and 4.6 months with placebo, 
with a 65% reduced risk of progression or death (HR 0.35; 
95% CI 0.27-0.45;p < 0.001). The estimated proportion of 
patients progression-free at 18 months were 34% (95% CI 
26-43) with everolimus and 9% (4-16) with placebo. This 
PFS was consistent at the subgroup analysis, regardless 
of age, gender, ethnicity, exposure to SSA, performance 
status, tumor differentiation. These findings are of utmost 
clinical relevance, since they suggest that everolimus 
may represent an effective treatment option in all patients 
with well-differentiated or moderately-differentiated 
pNET, without any parameter suggesting exclusion from 
treatment.
Overall survival (OS) did not differ between patients 
treated with everolimus or those assigned to placebo 
(HR, 1.05; 95% CI 0.71-1.55). This lack of advantage 
can probably attributed to the high proportion of patients 
(73%) who were crossed over from placebo to everolimus.
In line with other RADIANT trials, adverse events 
were mostly of grade 1 or 2 severity; however, some 
grade 3 or 4 events were more frequent with everolimus, 
including anemia (6% vs 0%) and hyperglycemia (5% vs 
2%). 
In a recent sub-analysis of the RADIANT 3 trial, 
the impact of previous chemotherapy on the efficacy 
everolimus was evaluated [17]. In total, 204 (50%) out of 
the 410 enrolled in the trial were chemo-naive. Everolimus 
prolonged PFS regardless of prior chemotherapy (prior 
chemotherapy group: 11.0 months with everolimus and 
3.2 months with placebo; HR 0.34; 95% CI 0.25-0.48;p < 
0.0001; chemo-naive group: 11.4 vs 5.4 months; HR 0.42; 
95% CI 0.29-0.60; p < 0.0001). 
rAdIAnt 4
The RADIANT-4 trial is a prospective, multicenter, 
randomized, double-blind, placebo-controlled, phase III 
study on patients with well-differentiated (G1 or G2) 
advanced NET of gastrointestinal (GI) or lung origin [13]. 
All patients had no history of and no active symptoms 
related to carcinoid syndrome, and had reported radiologic 
progression in the last 6 months. Enrolled subjects were 
randomly assigned, in a 2:1 ratio, to receive either 
everolimus 10 mg/day (n = 205) or placebo (n = 97) plus 
best supportive care. The primary endpoint was PFS. 
In total, 175 patients had GI NET and 90 had lung 
disease. At central review analysis, everolimus-treated 
patients showed a prolonged median PFS, as compared 
with those receiving placebo (11.0 vs 3.9 months, HR 
0.48; 95% CI 0.35-0.67; p < 0.00001). Overall similar 
results were observed at investigator assessment (14.0 vs 
5.5 months; HR 0.39; 95% CI 0.28-0.54; p < 0.00001). 
This benefit in PFS was consistent at all subgroup 
analyses: in particular, there was a 50% improvement in 
PFS for patients with lung tumors and a 44% benefit for 
those with GI NETs. Tumor shrinkage was observed in 
64% of patients assigned to the everolimus group and 26% 
of those in the placebo group. The objective response rate 
was 2% in the everolimus group and 1% in the placebo 
arm; on the other hand, disease control rate was 82.4% 
with everolimus and 64.9% with placebo. Death rates in 
the everolimus and placebo group were similar, although 
the everolimus group was treated longer. The first pre-
planned interim OS analysis suggested that everolimus 
might be associated with a reduction in the risk of death 
(HR 0.64; 95% CI 0.40-1.05; p = 0037, whereas the 
boundary for statistical significance was 0.0002) compared 
with placebo. Adverse events were consistent with the 
safety profile for everolimus.
dIscussIon
As a whole, the RADIANT studies showed that 
the introduction of everolimus in the pharmacological 
armamentarium for the treatment of NETs represents a key 
step forward in the therapy of this heterogeneous group 
of diseases. In fact, the efficacy and safety of everolimus 
have been consistently shown in well-differentiated NETs 
from all origins. Given the favorable results obtained in 
the pivotal studies, everolimus has been approved for the 
treatment of advanced pNETs and its approval procedure 
in GI and lung carcinoids is ongoing. However how this 
“pan-availability” of everolimus will influence clinical 
practice?
In pNETs, a number of therapeutic options such 
as sunitinib, SSAs, chemotherapy and peptide receptor 
radionuclide therapy (PRRT) are also available, while 
other agents - e.g. pazopanib - showed promising, although 
preliminary, results [18, 19]. At present, everolimus 
undoubtedly represents one of the most effective therapy 
options in this subset of patients, but its role within the 
therapeutic sequence (upfront therapy or after disease 
progression on chemotherapy/SSA) remains unclear. The 
subgroup analysis of the RADIANT 3 study showed the 
similar efficacy of everolimus in patients pretreated with 
chemotherapy and in those naïve for treatment [17]. On 
the other hand, the results of the recent phase II ITMO 
study, by Bajetta et al, suggest higher response rate and 
prolonged PFS with upfront everolimus combined with 
octreotide LAR, compared with administration at a later 
line of treatment [20]. Although the limited size and 
the different study design do not allow the comparison 
between the ITMO study and the RADIANT 3 trial, 
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Figure 1: treatment algorithm – proposed by the authors – for the treatment of lung carcinoids (Panel A) and of 
midgut G1-2 carcinoids (Panel b) after the publication of the rAdIAnt-4 trial.
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the study by Bajetta et al suggests further investigating 
the optimal therapeutic sequence for pNETs. Moreover, 
there is a need to find clinical and/or biological criteria to 
identify patients who can gain most benefit from upfront 
everolimus and those who may receive this molecule at 
progression from first-line treatment. 
At present, given the lack of head-to-head trials (the 
multicentric SEQTOR trial is still open for enrolment; 
NCT02246127), we believe that given its antiproliferative 
efficacy and tolerability profile everolimus can represent 
an ideal upfront treatment in G2 pNET patients, with 
rapidly-evolving disease and high disease burden. 
On the other hand, everolimus may represent an 
ideal second-line treatment for G1 pNET patients with 
indolent disease and low tumor burden after progression 
on SSA, in line with the results of the PROMID and 
CLARINET trials [21, 22]; these patients often present a 
long life expectancy and therefore tolerability and quality 
of life become crucial in selection of treatment. 
With respect to GI and lung carcinoids, the 
RADIANT 4 study will likely have a major impact on 
clinical practice, especially for lung NETs (Figure 1). 
Indeed, it was the first randomized study to specifically 
show that everolimus is significantly effective in patients 
with lung tumors. We believe that this study represent 
a major breakthrough, because, to date, there has not 
been any properly established treatment option for lung 
carcinoids. In particular, we think that everolimus may be 
particularly suitable for patients with more aggressive and 
rapidly progressing disease such as those with atypical 
carcinoids, in whom upfront treatment can be suggested. 
Moreover, data on second-line therapy with everolimus are 
even more grounded, also compared with those available 
for chemotherapy and PRRT, which are mostly derived 
from retrospective series or not-randomized studies in a 
mixed population of patients with typical carcinoids and 
subjects with atypical carcinoids.
With respect to GI carcinoids, we believe that, 
although the RADIANT 4 study showed promising 
results their impact on clinical practice will be less 
remarkable than for lung NETs. In fact, the RADIANT 4 
trial demonstrated the significant prolongation of PFS in 
patients with well-differentiated, advanced, progressive, 
nonfunctional NET regardless of lung or GI origin, as well 
as in site subgroups. However, the preplanned HR analysis 
by stratification factors of central review shows that when 
patients with better prognosis (appendix, caecum, jejunum, 
ileum, duodenum, and NET of unknown primary) are 
compared with those at worse prognosis (lung, stomach, 
rectum, and colon except caecum), a better HR for PFS 
was observed for patients with worse prognosis (0.43) and 
in those with moderately-differentiated NETs G2 patients 
(0.49). HR in the “better prognosis” subgroup was 0.63, 
and HR in patients with well-differentiated NETs G1 was 
0.57. Overall, these findings suggest that worse grade of 
differentiation and worse prognosis may be associated 
with higher efficacy of everolimus.
Based on these findings, we believe that the use of 
everolimus will be somehow limited in the upfront setting 
for “better prognosis” patients with appendix, caecum, 
jejunum, ileum, duodenum (midgut) NET, in whom a 
number of other treatment options such as SSA and PRRT 
are available. In addition, the approval for everolimus 
has been sought only for non-functioning patients, thus 
excluding from treatment functioning patients such as 
those with midgut carcinoids. Therefore, everolimus 
may be particularly suitable as upfront therapy or after 
progression for midgut patients with non-functioning 
G2 disease in whom SSA or PRRT therapy may be not 
indicated. 
On the other hand, for less indolent GI carcinoids, 
prospective evidence from the phase III RADIANT 4 is 
of paramount importance. In fact, with the exception of 
SSA [22, 23], other available therapeutic options, such as 
chemotherapy and PRRT, have been investigated only in 
retrospective or phase II not-randomized studies.
In conclusion, treatment of NETs can actually 
be quite complex, primarily because they are a highly 
heterogeneous group of tumors. We believe that 2015 has 
been a very exciting year for NETs management, because 
now we have many new studies that have provided us 
with new treatment options. The RADIANT studies, 
involving thousands of patients and several research 
Institutions all over the world, showed exciting results 
that show the “pan-availability” of everolimus across all 
NET subtypes likely allowing relevant improvements in 
patients’ care and a modification of therapeutic algorithms. 
The identification of the optimal treatment sequence(s), 
correct treatment timing and the selection of patients 
currently represent the issues to be explored in controlled 
clinical trials.
At present, a number of studies on the use of 
everolimus in the treatment of NET patients are ongoing 
or are awaiting their final results. The results of the 
RAMSETE trial (NCT00688623) will likely be released 
in late 2016: this single-arm, multicenter, phase II study 
evaluates everolimus monotherapy in the treatment of 
metastatic, non-syndromic NETs. In addition, everolimus 
is being investigated within different combination 
regimens with other targeted therapies (e.g., sorafenib 
[NCT00942682] or bevacizumab [NCT01229943]), 
temozolomide (NCT00576680 in patients with advanced 
pNETs and NCT02248012 in patients with advanced G3 
gastroenteropancreatic NETs), and even metformin (NCT 
02294006). Another intriguing combination therapy is the 
concomitant treatment with everolimus and pasireotide. 
This strategy is being assessed the COOPERATE-1 
study (NCT01263353), now completed, conducted in 
patients with advanced metastatic NETs and in the 3-arm, 
phase II LUNA trial (NCT01563354) which compares 
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everolimus+pasireotide LAR with the corresponding 
monotherapies in subjects with NET at lung/thymus.
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